Last reviewed · How we verify
Oxytocin Bolus
Oxytocin Bolus, marketed by Brigham and Women's Hospital, is a drug with a key composition patent expiring in 2028. Its primary strength lies in its established market presence and the strong clinical validation of oxytocin for its primary indication. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Oxytocin Bolus |
|---|---|
| Also known as | methylergonovine maleate (methergine) 0.2 mg IM, carboprost tromethamine (hemabate) 0.25 mg IM, misoprostol 600 mcg buccally |
| Sponsor | Brigham and Women's Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of Two Different Doses of Phenylephrine on Oxytocin Hemodynamic Effect (PHASE4)
- Prophylactic Regimen of Intravenous Oxytocin, Intravenous Tranexamic Acid, and Intramuscular Ergot Derivative for Primary Prevention of Postpartum Hemorrhage in Intrapartum Cesarean Section Versus Intravenous Carbetocin Alone (NA)
- Oxytocin Pharmacokinetics and Pharmacodynamics (PHASE2)
- Rectal Misoprostol for Reducing Blood Loss in Elective Cesarean Section (NA)
- Tranexamic Acid Versus Sublingual Misoprostol in Reducing Blood Loss During Elective CS in High Risk Cases (PHASE2)
- To Compare the Effects of Oxytocin and Carbetocin on Intraoperative Hemodynamic Changes in Cesarean Section Surgeries. (NA)
- Effects of Carbetocin and Oxytocin Used in Cesarean Sections on Postoperative Pain
- Comparing the Dose-response Profiles of Uterotonics After Initial Carbetocin Administration - an Ex-vivo Study in Desensitized Human Myometrium (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxytocin Bolus CI brief — competitive landscape report
- Oxytocin Bolus updates RSS · CI watch RSS
- Brigham and Women's Hospital portfolio CI